Heart Health & HeFH: Early Diagnosis & Treatment for a Long Life!

Heterozygous familial hypercholesterolemia (HeFH) is an inherited condition causing high LDL ("bad") cholesterol.

Effective treatments exist, but managing HeFH requires a proactive approach

Why HeFH Needs Early Attention:

• Genetic Predisposition: People with HeFH inherit a gene mutation affecting cholesterol processing, making LDL removal difficult.
• Early Onset: HeFH is present at birth, potentially leading to high cholesterol and increased heart disease risk throughout life.
• Treatment Complexity: While statins can be helpful, some patients may need combined medications or high doses, leading to side effects and adherence challenges.

The Power of Early Diagnosis & Treatment:

Despite these challenges, early diagnosis and proper HeFH management can significantly reduce the risk of heart disease.

Bempedoic Acid in the Spotlight: Phase 3 Trial Results Shine a Light on HeFH Treatment.

https://www.lipidjournal.com/article/S1933-2874(23)00355-0/fulltext

Pooled data from two 52-week phase 3 clinical trials of patients with:

1- Atherosclerotic cardiovascular disease and/or HeFH

2-Receiving maximally tolerated statin therapy (randomized 2:1 to bempedoic acid or placebo) was analyzed by HeFH status.

Results

1-Bempedoic acid significantly lowered LDL-C at week 12 vs. placebo regardless of HeFH status

with HeFH, ?21.2%;

without HeFH, ?18.2% [both P<0.0001]).

2-Bempedoic acid significantly reduced other lipid parameters

3-Bempedoic acid significantly reduced high-sensitivity C-reactive protein vs. placebo regardless of HeFH status (all P≤0.01).

4-Safety

adverse event incidence was comparable across all four groups (74.7–77.5%).

Zeta Pharma is the first pharmaceutical company in Africa and Middle-East region to offer Bempedoic acid 180mg tab (ZetaColest)

#zeta #zeta_pharma #zetacolest #bempedoic_acid #Genetics #Cholesterol #FH #CardiovascularHealth #EarlyDetection #PreventiveHealth #TreatmentAdherence #CardiovascularDisease